Oncimmune Holdings plc

Oncimmune Holdings plc specializes in creating and bringing to market advanced diagnostic technologies for cancer, serving regions across the United Kingdom, North America, Europe, and globally. A cornerstone product is EarlyCDT-Lung, an immunodiagnostic test specifically designed for the detection and identification of lung cancer. The company further advances its capabilities with SeroTag, a robust platform dedicated to discovering and validating biomarkers vital for patient stratification across numerous cancer types, infectious ailments, and a range of autoimmune disorders. Additionally, they provide NavigAID, a bespoke panel for disease characterization. Founded in 2015, Oncimmune Holdings plc operates from its base in Nottingham, UK.

Oncimmune Holdings plc trades as ONC.L on LSE. The company is classified in Healthcare / Biotechnology and reports in GBP.

The current profile places the business in Biotechnology. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows £2.74M of revenue and -£3.63M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Oncimmune Holdings plc can be compared against peers such as Destiny Pharma plc, DeepVerge plc, Hellenic Dynamics Plc, Kanabo Group Plc, LungLife AI, Inc., LungLife AI, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of £1.27M, beta of 1.81, and return on equity of +151.2%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

ONC.L currently shows total debt of £5.12M and beta of 1.81. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.oncimmune.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.